Contagion

The World Health Organization has declared the Ebola outbreak in West Africa to be an international public health emergency that requires an extraordinary response to stop its spread.

It is the largest and longest outbreak ever recorded of Ebola, which has a death rate of about 50 per cent and has so far killed at least 932 people.

"Countries affected to date simply do not have the capacity to manage an outbreak of this size and complexity on their own," WHO chief, Dr. Margaret Chan, said at a news conference in Geneva. "I urge the international community to provide this support on the most urgent basis possible."

In the United States, the Centers for Disease Control and Prevention have already elevated their Ebola response to the highest level and have recommended against travelling to West Africa. On Thursday, CDC director Dr. Tom Frieden told a Congressional hearing that the current outbreak is set to sicken more people than all previous outbreaks of the disease combined.

ZMapp TM is the result of a collaboration between Mapp Biopharmaceutical Inc. and LeafBio (San Diego, CA), Defyrus Inc. (Toronto, Canada), the U.S. government and the Public Health Agency of Canada (PHAC).

ZMapp TM is composed of three “humanized” monoclonal antibodies manufactured in plants, specifically Nicotiana.  It is an optimized cocktail combining the best components of MB-­‐003 (Mapp) and ZMAb (Defyrus/PHAC).

ZMapp TM was first identified as a drug candidate in January 2014 and has not yet been evaluated for safety in humans.  As such very little of the drug is currently available.  

Any decision to use an experimental drug in a patient would be a decision made by the treating physician under the regulatory guidelines of the FDA.

Mapp and its partners are cooperating with appropriate government agencies to increase production as quickly as possible.

CLICK HERE - ZMapp - Information Sheet (1 page .PDF file)

http://www.mappbio.com/

cnn.com - by By Jacque Wilson and Danielle Dellorto - August 5, 2014

(CNN) -- Two American missionary workers infected with the deadly Ebola virus were given an experimental drug that seems to have saved their lives.

Dr. Kent Brantly was given the medication, ZMapp, shortly after telling his doctors he thought he would die, according to a source familiar with his case. Within an hour, doctors say his symptoms -- labored breathing and a widespread rash -- dramatically improved. Nancy Writebol, another missionary working with Samaritan's Purse, received two doses of the medication and has also shown significant improvement, sources say.

As there is no proven treatment and no vaccine for Ebola, this experimental drug is raising lots of questions.

(READ COMPLETE ARTICLE)

Three top secret, experimental vials stored at subzero temperatures were flown into Liberia last week in a last-ditch effort to save two American missionary workers who had contracted Ebola, according to a source familiar with details of the treatment.

On July 22, Dr. Kent Brantly woke up feeling feverish. Fearing the worst, Brantly immediately isolated himself. Nancy Writebol's symptoms started three days later. A rapid field blood test confirmed the infection in both of them after they had become ill with fever, vomiting and diarrhea.

READ COMPLETE ARTICLE